Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 4/20 | 0.35 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17791681 | 0.97 | CYP2C19 (0.56) | CYP2C19TBXAS1TSHRUSP2ALDH1A1 | |
| SCHEMBL16730622 | 0.92 | — | — | |
| SCHEMBL10641493 | 0.87 | — | — | |
| SCHEMBL11698845 | 0.82 | CYP2C19 (0.44) | CYP2C19TSHRUSP2ALDH1A1LMNA | |
| SCHEMBL27753016 | 0.81 | CYP2C19 (0.56) | CYP2C19TBXAS1TSHRUSP2ALDH1A1 | |
| SCHEMBL9342816 | 0.79 | CYP2C19 (0.65) | CYP2C19TBXAS1TSHRUSP2ALDH1A1 | |
| SCHEMBL9183557 | 0.79 | CYP2C19 (0.65) | CYP2C19TBXAS1TSHRUSP2ALDH1A1 | |
| SCHEMBL125690 | 0.79 | CYP2C19 (0.65) | CYP2C19TBXAS1TSHRUSP2ALDH1A1 | |
| SCHEMBL9180415 | 0.79 | CYP2C19 (0.65) | CYP2C19TBXAS1TSHRUSP2ALDH1A1 | |
| SCHEMBL11699716 | 0.79 | CYP2C19 (0.41) | CYP2C19MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903979-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS INC (US) | 2020-08-19 | — | — | EP | claimed |
| US-9359376-B2 | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds | SPHAERA PHARMA PTE. LTD (SG) | 2016-06-07 | — | — | US | claimed |
| WO-2023202604-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 中国科学院上海药物研究所 | 2023-10-26 | — | — | WO | disclosed |
| CN-109071418-B | Prodrugs of amino acid derivatives | 大正制药株式会社 | 2022-03-18 | — | — | CN | disclosed |
| US-20150266814-A1 | METHODS, COMPOUNDS, AND COMPOSITIONS FOR DELIVERING 1,3-PROPANEDISULFONIC ACID | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2015-09-24 | — | — | US | disclosed |
| US-9051248-B2 | Methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid | BHI LIMITED PARTNERSHIP (CA) | 2015-06-09 | — | — | US | disclosed |
| US-20120208850-A1 | METHODS, COMPOUNDS, AND COMPOSITIONS FOR DELIVERING 1,3-PROPANEDISULFONIC ACID | BELLUS HEALTH INC. (CA) | 2012-08-16 | — | — | US | disclosed |
| EP-2464626-A1 | METHODS, COMPOUNDS, AND COMPOSITIONS FOR DELIVERING 1,3-PROPAN ED ISULFONIC ACID | Bellus Health Inc. (CA) | 2012-06-20 | — | — | EP | disclosed |
| WO-2011017800-A1 | METHODS, COMPOUNDS, AND COMPOSITIONS FOR DELIVERING 1,3-PROPAN ED ISULFONIC ACID | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2011-02-17 | — | — | WO | disclosed |
| EP-0266690-A2 | Method for the production of 2,2-disubstituted 3-chlorpropionic acid esters | BASF Aktiengesellschaft (DE) | 1988-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208850-A1 | METHODS, COMPOUNDS, AND COMPOSITIONS FOR DELIVERING 1,3-PROPANEDISULFONIC ACID | SGMS1, GSS, HPGDS | CYP2C19 1063/4885TBXAS1 746/4885TSHR 4689/4885 |
| US-20150266814-A1 | METHODS, COMPOUNDS, AND COMPOSITIONS FOR DELIVERING 1,3-PROPANEDISULFONIC ACID | SGMS1, GSS, HPGDS | CYP2C19 1063/4885TBXAS1 746/4885TSHR 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.